PHASE I/II IPAX-2 STUDY

IPAX-2 (Phase I/II)

  • Study title: 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma
  • Study description: An open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of care in newly diagnosed GBM patients.
  • Trial status: Recruiting
  • Trial identifier: NCT05450744
  • Sponsor: Telix International Pty Ltd
  • Investigational asset: 131I-IPA
  • Condition: Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme
  • Ages eligible for study: 18 years to 65 years
  • Gender: All
  • No healthy volunteers

CLINICAL RATIONALE

PRIMARY OUTCOME MEASURES

ELIGIBILITY: INCLUSION CRITERIA

ELIGIBILITY: EXCLUSION CRITERIA

GET IN TOUCH FOR MORE ON THE TRIALS